What is the evidence for using greater occipital nerve blocks in adult patients with episodic or chronic migraine refractory to standard acute and preventive treatments?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Greater Occipital Nerve Blocks in Migraine: Evidence-Based Recommendation

Greater occipital nerve (GON) blocks with local anesthetics are effective for chronic migraine refractory to standard treatments, with evidence supporting significant reductions in headache frequency and intensity, though they are not mentioned in current major treatment guidelines as first-line therapy.

Evidence Quality and Guideline Context

The 2021 Nature Reviews Neurology guideline 1 establishes the evidence-based hierarchy for chronic migraine prevention: topiramate as first-line, followed by onabotulinumtoxinA and CGRP monoclonal antibodies after 2-3 preventive medication failures. Notably, GON blocks are not mentioned in this comprehensive guideline, suggesting they occupy a niche role rather than standard care.

However, the 2025 evidence-based guidelines from the Italian Society for the Study of Headache and International Headache Society 2 acknowledge the evolving landscape of migraine treatment, though specific recommendations for GON blocks require examination of primary research evidence.

Research Evidence for GON Blocks

Efficacy Data

The strongest placebo-controlled evidence comes from a 2023 randomized trial 3 demonstrating:

  • Significant reduction in headache days: -4.2 days vs placebo (95% CI: -7.5 to -0.8; p=0.018)
  • Significant reduction in migraine days: -4.7 days vs placebo (95% CI: -7.7 to -1.7; p=0.003)
  • 40.9% achieved ≥50% reduction in headache days vs 9.1% with placebo (p=0.024)
  • Protocol: Four-weekly bilateral GON blocks with 2% lidocaine (40mg) for 12 weeks

A 2017 placebo-controlled study 4 corroborated these findings with bupivacaine, showing sustained benefits through 3 months of follow-up, while placebo effects dissipated after the first month.

Comparative Effectiveness

Recent 2026 data 5 compared GON blocks directly with standard treatments:

  • OnabotulinumtoxinA (both via GON block and PREEMPT protocol) provided the most rapid and substantial benefit
  • PREEMPT protocol reduced MIDAS scores from 3.74 to 1.30 at 3 months (p<0.001)
  • Monoclonal antibodies provided progressive, sustained improvement
  • All interventions were effective, but onset and magnitude differed

A 2026 head-to-head comparison 6 found GON blocks superior to sphenopalatine ganglion blocks in reducing monthly migraine days.

Long-term Outcomes

The 2026 pulsed radiofrequency study 7 demonstrated:

  • 60.3% achieved Patient Acceptable Symptom State at 12 months
  • Mean monthly headache days reduced from 14.3 to 6.1 (p<0.001)
  • Higher baseline pain scores predicted better long-term success (OR: 1.62)
  • Early response at one month predicted sustained benefit

Evidence Quality Concerns

The 2022 meta-analysis 8 provides critical context:

  • Overall quality of evidence rated as "very low" due to substantial risk of bias and imprecision
  • Trial sequential analysis was inconclusive
  • Small sample sizes and high risk of bias in included trials
  • Adding corticosteroids showed no additional benefit (MD: -1.1 days, 95% CI: -4.1 to 1.8, p=0.45)

Clinical Algorithm for GON Blocks

When to Consider GON Blocks:

  1. After failure of guideline-recommended treatments 1:

    • Topiramate trial completed
    • Consider before or alongside onabotulinumtoxinA or CGRP antibodies based on access and cost

  2. Patient characteristics favoring GON blocks 7:

    • Higher baseline pain intensity (VAS scores)
    • Occipital pain component
    • Contraindications to systemic preventives

  3. Protocol based on strongest evidence 3:

    • Bilateral GON blocks with 2% lidocaine (40mg total, 2ml per side)
    • Four-weekly injections for 12 weeks
    • Ultrasound guidance improves accuracy 5

Expected Outcomes:

  • Anticipate 40% achieving ≥50% headache reduction 3
  • Mean reduction of 4-5 headache/migraine days per month 3
  • Assess response at 1 month to predict long-term success 7
  • Effects may persist 3+ months after treatment course 4

Safety Profile

All studies reported mild, transient adverse events with no serious complications 3, 8, 4. The safety profile is favorable compared to systemic preventives, making GON blocks particularly attractive for patients with medication intolerance.

Critical Caveats

The evidence base remains limited despite positive findings 8. The "very low" quality rating reflects:

  • Small total patient numbers across trials
  • Methodological concerns in most studies
  • Lack of standardized protocols
  • Insufficient head-to-head comparisons with guideline-recommended treatments

GON blocks should not replace evidence-based preventives 1 but rather serve as an adjunctive or alternative option when standard treatments fail or are contraindicated.

Practical Implementation

For patients with chronic migraine refractory to topiramate:

  • Consider GON blocks as a reasonable option alongside (not instead of) onabotulinumtoxinA or CGRP antibodies
  • Use 2% lidocaine, bilateral, four-weekly for 12 weeks 3
  • Evaluate response at 1 month; lack of early response predicts poor long-term outcome 7
  • Ultrasound guidance optimizes technique 5
  • Do not add corticosteroids—no proven benefit 8

The decision between GON blocks and guideline-recommended treatments (onabotulinumtoxinA, CGRP antibodies) should weigh cost, availability, patient preference, and comorbidities, recognizing that onabotulinumtoxinA provides more robust evidence for chronic migraine 1, 5.

References

1
Guideline

diagnosis and management of migraine in ten steps.

Nature Reviews Neurology, 2021

2
Research

Evidence-based guidelines for the pharmacological treatment of migraine, summary version.

Cephalalgia : an international journal of headache, 2025

Related Questions

What is the best medication to treat chronic occipital headaches?
In a 40‑year‑old male who had heat‑stroke after a heavy gym session and now presents with several days of fever, chills, night sweats, myalgias, mild shortness of breath, chest discomfort, photosensitivity, a history of migraines, and recent cervical spine surgery, what evaluation and management steps are recommended?
How should the laboratory findings—borderline macrocytosis, mild monocytosis, and mildly reduced renal function—in an 89‑year‑old woman with migraine and urinary tract infection who is taking hyoscyamine, clopidogrel, metoprolol, amlodipine, rosuvastatin, and nortriptyline be interpreted?
What is the textbook definition of a migraine?
What are the 2025 American Headache Society guidelines for emergency department management of migraine?
Which fruits are high in sodium and should be avoided in patients with decompensated cirrhosis?
What is the likely cause of blue discoloration of the feet in an 18-year-old male with a normal lower-extremity Doppler study?
Do fresh citrus fruits contain sodium, allowing a patient with decompensated cirrhosis on a low‑sodium diet to eat them safely?
Which statins are preferred for a patient with coronary artery disease after percutaneous coronary intervention who also has chronic liver disease?
What treatment is recommended for a red dot and pain on the glans penis?
In a patient with ascites and a total bilirubin of 3.5 mg/dL who is on a high‑intensity statin, what is the appropriate management of the statin therapy and how should the ascites be treated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.